» Articles » PMID: 34495339

Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review

Overview
Journal JAMA Netw Open
Specialty General Medicine
Date 2021 Sep 8
PMID 34495339
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Importance: Individuals with chronic pain who use long-term opioid therapy (LTOT) are at risk of opioid use disorder and other harmful outcomes. Rotation to buprenorphine may be considered, but the outcomes of such rotation in this population have not been systematically reviewed.

Objective: To synthesize the evidence on rotation to buprenorphine from full μ-opioid receptor agonists among individuals with chronic pain who were receiving LTOT, including the outcomes of precipitated opioid withdrawal, pain intensity, pain interference, treatment success, adverse events or adverse effects, mental health condition, and health care use.

Evidence Review: PubMed, CINAHL, Embase, and PsycInfo were searched from inception through November 3, 2020, for peer-reviewed original English-language research that reported the prespecified outcomes of rotation from prescribed long-term opioids to buprenorphine among individuals with chronic pain. Two independent reviewers extracted data as well as assessed risk of bias and study quality according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guidelines. Quality of evidence was assessed with the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

Findings: A total of 22 studies were analyzed, of which 5 (22.7%) were randomized clinical trials, 7 (31.8%) were case-control or cohort studies, and 10 (45.5%) were uncontrolled pre-post studies, which involved 1616 unique participants (675 female [41.8%] and 941 male [58.2%] individuals). Six of the 22 studies (27.3%) were primary or secondary analyses of a large randomized clinical trial. Participants had diverse pain and opioid use histories. Rationale for buprenorphine rotation included inadequate analgesia, intolerable adverse effects, risky opioid regimens (eg, high dose and/or sedative coprescriptions), and aberrant opioid use. Most protocols were adapted from protocols for initiating treatment in patients with opioid use disorder and used buccal or sublingual buprenorphine. Very low-quality evidence suggested that buprenorphine rotation was associated with maintained or improved analgesia, with a low risk of precipitating opioid withdrawal. Steady-dose buprenorphine was better tolerated than tapered-dose buprenorphine. Adverse effects were manageable, and severe adverse events were rare. Only 2 studies evaluated mental health outcomes, but none evaluated health care use. Limitations included a high risk of bias in most studies.

Conclusions And Relevance: In this systematic review, buprenorphine was associated with reduced chronic pain intensity without precipitating opioid withdrawal in individuals with chronic pain who were receiving LTOT. Future studies are necessary to ascertain the ideal starting dose, formulation, and administration frequency of buprenorphine as well as the best approach to buprenorphine rotation.

Citing Articles

Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline.

Davis M, Davies A, McPherson M, Reddy A, Paice J, Roeland E Support Care Cancer. 2025; 33(3):243.

PMID: 40029420 DOI: 10.1007/s00520-025-09286-z.


Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical Trial.

Becker W, Seal K, Nelson D, DeRonne B, Kats A, Morasco B JAMA Intern Med. 2025; .

PMID: 39960730 PMC: 11833656. DOI: 10.1001/jamainternmed.2024.8361.


Comparison of the Efficacy of Transdermal Buprenorphine Versus Ketoprofen Patches for Post-operative Analgesia in Total Knee Arthroplasty: A Randomised Controlled Trial.

Nayak T, Ojha M, Ansari M, Sehrawat S, Shankar V, Kumar S Cureus. 2024; 16(10):e72382.

PMID: 39583367 PMC: 11586068. DOI: 10.7759/cureus.72382.


Frontline Perspectives on Buprenorphine for the Management of Chronic Pain.

Adler J, Mallick-Searle T, Garofoli M, Zimmerman A J Multidiscip Healthc. 2024; 17:1375-1383.

PMID: 38563040 PMC: 10982663. DOI: 10.2147/JMDH.S449748.


Opioid characteristics and nonopioid interventions associated with successful opioid taper in patients with chronic noncancer pain.

Jung M, Xia T, Ilomaki J, Pearce C, Nielsen S Pain. 2023; 165(6):1327-1335.

PMID: 38112755 PMC: 11090027. DOI: 10.1097/j.pain.0000000000003133.


References
1.
Baser O, Chalk M, Fiellin D, Gastfriend D . Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011; 17 Suppl 8:S235-48. View

2.
Lutfy K, Eitan S, Bryant C, Yang Y, Saliminejad N, Walwyn W . Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003; 23(32):10331-7. PMC: 6741014. View

3.
Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi Jr J . Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014; 15(12):2087-94. DOI: 10.1111/pme.12520. View

4.
Mendelson J, Upton R, Everhart E, Jacob 3rd P, Jones R . Bioavailability of sublingual buprenorphine. J Clin Pharmacol. 1997; 37(1):31-7. DOI: 10.1177/009127009703700106. View

5.
Bentzley B, Barth K, Back S, Book S . Discontinuation of buprenorphine maintenance therapy: perspectives and outcomes. J Subst Abuse Treat. 2015; 52:48-57. PMC: 4382404. DOI: 10.1016/j.jsat.2014.12.011. View